What is it about?
This article is a comprehensive review of EGFR-TKIs as first-line treatment for patients with advanced NSCLC. In addition to comparing osimertinib (standard of care) with first- and second-generation TKIs, this review also compares first- and second-generation TKIs with each other. Further, this review discusses the cost-effectiveness of osimertinib in comparison with first-and second-generation TKIs.
Featured Image
Why is it important?
This study reviewed articles that assessed tyrosine kinase inhibitors (TKIs) for advanced NSCLC and developed an appropriate treatment plan for patients in low-income countries.
Perspectives
This article helps oncologists with limited resources to decide on treatment for EGFR-positive NSCLC and also helps researchers by reviewing and discussing RCTs.
Mousa Alali
Damascus University
Read the Original
This page is a summary of: Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review, Journal of Immunotherapy and Precision Oncology, June 2023, Innovative Healthcare Institute,
DOI: 10.36401/jipo-22-29.
You can read the full text:
Contributors
The following have contributed to this page
